RESEARCH PAPER
The direct costs of drug-induced skin reactions
 
More details
Hide details
1
Department of Dermatology, Military Institute of Medicine, Warsaw, Poland
2
Department of Immunology and Allergology, Military Institute of Medicine, Warsaw, Poland
 
Ann Agric Environ Med. 2017;24(2):190–193
KEYWORDS:
ABSTRACT:
Objective:
The aim of the study was an assessment of direct costs of patients hospitalised for for skin adverse drug reactions during 2002–2012 in the Department of Dermatology at the Military Institute of Medicine (Ministry of Defence) in Warsaw. The analysis was carried out from the perspectives of the public payer and service provider.

Material and Methods:
The retrospective study was carried out in a group of 164 adult patients due to skin adverse drug reactions. Analysis was based on data from patient medical records and medical orders which provided information on the used resources, including diagnostic tests, medical consultations, medicinal products, hospitalisation duration, together with cost estimation, regardless of the treatment being the cause of the skin reaction.

Results:
According to the International Statistical Classification of Diseases and Related Health Problems(ICD) diagnosis and scores, assigned by the National Healthcare Fund, it has been estimated that patient hospitalisation at the Department of Dermatology for skin drug reaction incurred costs at the average amount of €717.00 per patient. The complex diagnostics and pharmacotherapy of the same group of patients generated costs for the hospital at the average amount of €680 per patient.

Conclusions:
As a result of the analysis, the therapy for skin adverse drug effects generates significant costs, both for the payer and the service provider. Since the costs are comparable, it seems that the pricing of medical procedures by the public payer is adequate for the costs incurred by the medical service provider.

CORRESPONDING AUTHOR:
Monika Szkultecka – Dębek   
Department of Dermatology, Military Institute of Medicine, Warsaw, Poland
 
REFERENCES (12):
1. Laurence DR, Bennett PN, Brown MJ. Clinical Pharmacology, 8thedn. London: Churchill Livingstone, 1997.
2. Skibicka I, Maciejczyk A. Bezpieczeństwo farmakoterapii a zgłaszanie niepożądanych działań leków. Neurol. Neurochir. Pol. 2004; 84, 503–10.
3. Stausberg J, Hasford J. Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinalanalysis from 2003 to 2007 of ICD-10-coded routinedata. Health Services Research 2011; 11:134.
4. Burbach, GJ, Zuberbier T. Diagnosis of drug-induced skin reactions: a future role for computer-aided systems? Curr Opin Allergy Clin Immunol. 2011 OCT; 11(5): 451–6.
5. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker M, Saljé K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiology and drug safety 2011; 20: 626–634.
6. Pattanaik S, Dhamija P, Malhotra S, Sharma N, Pandhi P. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. Br J Clin Pharmacol. 2009 Mar; 67(3): 363–9.
7. Więczkowska H, Bryl W, Hoffmann K. Costs of diagnosis and treatment of hypertension in the department of internal diseases, Forum Zaburzeń Metabolicznych 2011, tom 2, nr 3, 177–183.
8. Kusowska J. Economic evaluation of treatment of community acquired respiratory tract infections. Farmakoekonomika 1/2001.
9. Grabowski J, Kozierkiewicz A, Gajek F. Polski system jednorodnych grup pacjentów, Służba Zdrowia nr 80–81, 18 października 2001.
10. Giuliani J, Indelli M, Marzola M, Raisi E, Frassoldati A. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience Tumori 2012 Jul-Aug; 98(4): 408–12.
11. Rottenkolber D, Hasford J, Stausberg J. Costs of adverse drug events in German hospitals – a microcosting study. Value In Health (2012)8 68–875.
12. Pattanaik S, Dhamija P, Malhotra S, SharmaN, Pandhiet P. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. British Journal of Clinical Pharmacology, Volume 67, issue 3 (March 2009), p. 363–369.
eISSN:1898-2263
ISSN:1232-1966